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Objmives. The present study was performed to determine the 
systemic and p”tnlo”sry hemalynamie eve45 or *mri”D”e in 
Infants ar.d tidren with a cardiac left t” right shunt to detrrmine 
if ihere is a bonekill &eel on ihe pathaphysiolegy of this 
condition. 
Background. Amrinane is a bipyridine derivative nilh inotrup 
ie and vawditstw effect? that have nut been systematically erat- 
uated in the podiatric psfient with increased pubnmary blood 
nos. 
Mclkadc. Nineteen pntknts (aged 2 months to 8.3 years) with 
one or nare kft to right shunk were evnlunted uring cordioc 
c%thcterisatin with direct hem@namk meawements made 
b&ore %ttd 10 mtn @cab etfcct) alter administration of % b&s 
b&don ofmnrinoae, 3 mgng bony might. The Ftk method aas 
used to catc”tate pulmonsr) and s,stemie blmd Row. %ld r&s- 
Uuwes were thrn cabzutated. 
. . 
nnau f,ulmoas,y artery prpsrurc by 19%, me”” WI &it pres- 
sure by 39% sod systemic vrrxular mtstuuce by 17%. In gruup 
B, se”L11 prtknts with p”hnuMry artery hypertension ,nlean 
Children with a large cardiac left to right shunt are frequently 
encountered in the practice of pediatric cardiology and 
cardiovascular surgery. Although digoxin and diuretic 
agents have provided the primary mode of phamxotherapy 
for decades. many investigutors challenge their effectivene;r 
because the underlying pathophysiologic features result in 
symptoms that may represent pulmonary circulatory conges- 
tion rather than mywardial contructile failure. Still. there 
are both anecdotal and objective data to support the benefits 
of such therapy (1). 
These pathophysiologic features led to the suggestion :hat 
vasodilators may have a Lxnelicial role in the clinical setting 
by lowering systemic vascular resistance, resulting in in- 
creased cardiac output and decreased pulmonary blood flow. 
This hypothesis has been supponed in multiple studier (2-81 
monq r&t”nce by‘47% and 




Conctusions. In chit&w Hith a car&w teft to right skurt, 
“mrinwe 1) appears to hare sdcctire rasoditcr etferts depend- 
ing on the putnwwy artery prersure and r&t%w 2) hnr 1 
benefirial hemodynamir etTect in cbiiren with nowal pu~Uy 
urtery prcIs”I‘e and iv&is-, “ml 3) “lay buve u Ia in Ibe 
treatment af ptients with pubmmary arteq hyperteOrio0 without 
causing systemic bypoltnssn. 
(I Am CnU &r&l 1993;21:1461-5) 
using several vascdilating “gents in ba!h humans and aui- 
mals with a large left to right shunt. 
Amiinone is a nonglycoside. noncarecholamine bipyn- 
dine denvntive that possesses both potent positive inotropic 
and systemic vasodilating etiects. Its mechanism of action 
involks selective inhibition of phosphodiesterase III that 
indirectlv results in an increase in intracellular cyclic aden- 
osine m&ophosphute production (9) 
The preskt dudy &as performed to evaluate the in viva 
hemodynamic effects ofamrinone on the pathophyniology of 
left to right shunts in children and to determine whether this 
“gent may be of benefit in the clinical setting. 
Study patient% The study group consisted of I9 patients. 
2 months to 8.3 years old. with 3 left to right shunt. There 
were 9 girls and IO boyi and 8 had trisomy 21. The left to 
right cardiar shunts corsisted of, alone or in combination, 
atrial septal defect, ventricular scptal defect. endomdial 
cushion defect or patent ductus aneriosus (Table I). 
All patient, were maintained on combinations of digoxin. 
aorta. Pulmonary and systemic Row were calculated using 
the Fick method and indexed for body surface area. The 
pulmonary/systemic Row (QJQ,) ratio, systemic vascular 
resistance. total pulmonary vascular resistance, pulmonary 
arteriolar resistance, pulmonary artericlar resistance/ 
systemic vaxdar resistance ratio. volume of left tc right 
shunt and stroke volume were then calculated. Oxygen 
consumption was measured accuratelv in I5 of 19 patients bv 
the cc&inucus flow-through methbd using the Waters 
MRM-2 instrument (IO) and was assumed in the remaining 
four patients. Cardiac angiography was not performed until 
all hemodynamic dsta had been obtained. Platelet ccunt and 
liver function tests were obtained after completion of the 
study, and am&one plasma levels were obtained within 10 
to 25 min after the initial bclus to ensure therapeutic levels. 
Pulmonary artery hypertension was defined as a mean 
pulmonary artery pressure >20 mm Hg (II) and elevated 
total pulmonay resistance as >3 Weed U,rn’ (12). Five 
patients with a mean control pulmonary artery pressure 
520 mm Hg and total pulmonary resistance 53 Wood Um’ 
were assigned tc grcup A; seven with a mean control 
pulmcnary artery pressure z-20 mm Hg and total pulmcnaty 
resistance 53 Wood L%m’ tc group B, and seven with a 
mean pulmonary artery pressure >20 mm Hg and control 
total pulmonary vascular resistance 23 Wood U.rn’ to group 
C. 
ASD = atrlal septaldcfect:Cp = ca#oprit: D,g = dwin: Da = d,urst,ss 
tfuraremide or rpironolactone): ECD = andoeardrd cushion defect: F = 
Statistics. The Student I test for paired observation was 
fernale: M = nl*lL; PA” = p”l.o”BlyBltely h penlnrian: PAP = pulmonary 
used to compare differences between ccntrcl and postdrug 
artery prcirurc; PDA = pawn, dwtw aneriosur: pt = patient: TPR = 10111 mean values. A p value c 0.05 was considered significant. 
pulmonary resismnce. TriZ, = lrisomy 21: “SD = ventricular sepmt drRct: All values were reponed as mean value f SD. 
w* = Wli&?h,. 
Results 
lions were held I2 h befcre thk study. The study was 
diuretic drugs or afterload reducers. Four patients (Patients 
approved by the Institutional Human Xesearch Committee, 
and informed ccwent was obtained from the patients‘ par- 
ents before the study. 
I, 4, I3 and 18) did not receive any medication. All medica- 
Patients received either meperidine. prcmethazine hydro- 
chloride or chlotpmmazine intramuscularly or chloral hy- 
drate orally as premeditation. One patient received midazo- 
lam intravenously as premeditation. All patients were 
studied in the fasting state and in the supine position. 
All patients underwent percutaneous right and leh heart 
catheterization. Amrinone was given as a bolus 3 m& 
body weight, infusion at a rate of I mgls into the pulmonary 
artery in 17 patients: during the early stage of the study. the 
bolus was infused into tt.e left ventricle of I patient and into 
a peripheral vein in another. Heart rate and the following 
pressure data were obtained before and 10 min after the 
amrinone bclus dose: aortic (systolic and mean). main pul- 
mcnary. left at&l or pulmonary capillary and right atrial. 
Using the same prctcccl, oxygen saturation (by Waters 
Oxicom 2000) was measured in the superior vena cava, left 
atrium or pulmonary capil!aries, main puhnonary artery and 
pulmonaryarte~y pressure by 1-M (from IS.6 t 3.4 to 
12.6 5 2.8 mm Hg, p < 0.05). left atrial mean pressure by 
39% (from 5.6 2 I.5 to 3.4 r I.7 mm Hg, p c 0.05) and 
Croup A (normal pulmmwry artery prtwre and r&s- 
systemic vascular resistance by 17% (from 17.1 f 5.4 tc 
tax). in arcup A, amrinone sirmilicantly reduced mean 
14.2 t 3.7 Wood tJ,m’, p < 0.05). Although there were small 
decreases in pulmonary flow index (%L volume of left to 
right shunt (14%) and QJQ. ratio (16%), and a small increase 
in systemic Row index (5%), these differences were not 
significant. There were no significant changes in mean or 
systolic aortic pressure. pulmonary arteriolar resistance. 
total pu!monary resistance, pulmonary aneriolar resistance/ 
systemx vascular resistance ratio. heart rate. stroke volume 
and cxygen consumption (Table 2). 
Group B (increased pulmonary artery pressure and normat 
resistance). In group B. amrinone significantly reduced the 
mean pulmonary artery pressure by 27% (from 37 + 7.8 to 
27 + 4.8 mm Hg. p < O.OOS), systolic acrtic pressure by 5% 
(from 78 t 5.3 to 74 _c 6.2 mm Hg. p < O.OI), mean acrtic 
prew.ue by 12% (from 57 t 4.0 to 50 * 2.0 mm Hg, p < 
0.05). pulmonary artericlar resistance by 36% (from 1.4 f 
0.4 to 0.9 + 0.3 Wood U.m’, p < 0.05) and total pulmonary 
resistance by 26% (from 1.9 5 0.6 to 1.4 z 0.5 Wwd U.0;‘. 
p < 0.05). Although the mean values ,howed an overall 
decrease in QPIQS ratio. this ratio increased after amrinone 
dministntion in Patients 6, 7 and 8, with left to right 
shu,; volume increasinc in Patients 7 2nd 8. Svstemic Row 
index, pulmonary Aow index. left atrial mean pressure. 
systemic vascular resistance, pulmonnry nrteriolarlsystemic 
vascular resistance ratio, stroke volume. heart rate or oxy- 
gen consumption did not change significatttiy tn group B 
(Table 2). 
Gmup C (increased pulmonary artery presswc and resis- 
tan@. In group C. am&e significantly reduce@ the pulnto- 
nary artery pressure by 22% (from 54.9 c 15 to 42.7 5 
I5 mm Hg; p’< O.C@S!. p&onaty atteriolar esistanx by 4% 
(from 6.7 t 2.9 to 3.4 i 2.0 Wood U,m’. p < O.tMI: to&l 
pulmonary resistance by 41% (from 7.8 ? 3.3 to 
4.1 L 2.3 Wood Ll,m’. p < O.WS [Fig. II) and pulmonary 
artetiolarisystemic vascuIar resistance mtio by 45% (from 
0.33 2 0.13 to 0.18 z 0.10. p < O.CO5). As expected with 
a decrease in pulmoneq vascuku resistance. pulmonary flow 
index increased significzntly by 58% (fmm 7.9 + 2.9 to 12.5 c 
6.5 literrlmin per ml, p < 0.05): and the volume of 
lefttorigbt shunt increased by94% (fmm4.7 2 2.4 109.1 ? 6.5 
literslmin per mz. p < 0.05); the QJQ, ratio increased by MEG 
(p = NS). Heart rate increased significantly by 15% (from 
I44 2 I3 to I65 + 21 beats/mitt. p < O.oUS). There were no 
significant changes in systemic flow index. menn or systolic 
aonic pressure, mean left attial pressure. systemic vascuku 
resistance. stroke volume or oxygen consumption (Table 2). 
Or&en consumption. This variable was measured accu- 
rately m all except Patie& 2.6. IO and I?. In group A, after 
amrinone administration, oxygen consumption increased from 
3% to 65%. In group B, the oxygen consumption response was 
vnnahle. increasing in two patients and ecreasing iti two: in 
three plientr, oxygen consump:ion was not measwed. In 
gwq C, oxygen consumption increased in five patients, de- 
creased in one patient and did not change in one patient. 
Amrinone plasma levels. These levels were obtained in IO 
of the 19 study patients. Values obtained IO to 25 min after 
amrinone administration ranged from 2.2 to 7.5 &ml, levels 
previously reported (9) 10 be in the therapeutic range. 
Postdrug platelel ewnt and liver fun&n te&. These 
were performed in 14 of 19 patients. Patients I and 15 
had mild elevation of aspertete aminotrensferase (69 and 
57 U/liter, respectively [normal 0 to 401) after amrhwne 
infusion. Platelet counts remained normal. There were no 
other significant complications, although Patient I had a 
Cmin episode ofjunctional rhythm associated with transienl 
hypzezio; :: mir, ztcr arKkloni iiifaiorl. 
Discussion 
The role of digorin and diuretic agents in rhe treatment of 
infants who are symptomatic from a large cardiac left to right 
shunt remains controversial. Vasodilators have been used in 
these oatients in an attemat IO decrease the demee of left to 
tight shuntingand thereS~:irxrease systemic output, improv- 
ing oxygen delivery to the tisws. We hypothesized that 
amrinone may act in a similar mwner with the added benefit 
of a direct inotropic action. 
Seleelive hemodynamic e&ts ofsmrinone. In this study. 
amrinone had beneficial hemodynamic e6ects in patients 
with normal pulmonary artery pressure and normal total 
pulmonary resistance: amrinone significantly reduced the 
left atrial mean pressure, systemic vascular resistance and 
pulmonary artery pressure. The decrease in left atrial mean 
pressure presumably resulted from the positive inotropic or 
the aftelloading effects of amrinone because pulmonary 
blood Row did not decrease significantly. 
In patients with pulmonary artery hypertension and nor- 
mal total pulmonary resistance, amrinone had ditTerent va- 
sodilator effects. In these vatients. the grow most corn. 
manly seen clinically. amrinbne decreased~ul~onary artery 
oressure bv 27%. total mdmonarv resistance bv 26%. SYE- 
i01iC %~TI~C~!XBSUE by &and me& aortic preS& by I?%. 
Thus, pulmonary flow did not change signihcantly to in- 
crease the degree of the left to right shunt. However, in three 
of seven patients the QJQ, ratio did increase, indicating a 
possible detrimental et&t of amrinone in this group. 
Most important, in patients with elevated pulmonary 
artery pressure end elevated total pulmonary resistance, 
amrinone decreased the total pulmonary resistance. rcso!t- 
ing in an increase in pulmonary blood flow, QJQ, and left to 
right shunt volume. 
Overall in the three groups. the resuits indicate that 
amrinane may have selective vasodilator properties depend- 
ing on the magnitude of pulmonary artery pressure and 
resistance. In patients with normal pulmonary artery pres. 
sure and total pulmonary resistance. amrinone reduced the 
systemic vascular resistance to a greater degree than il 
reduced total pulmonary resistance. In patients with ele. 
Figure 2. Percent decrease in mean resiwece after amrinone infu- 
sion in the !hree patient gmups. SeUd bus represent systemic 
~asculer resistance and open bars show pulmonary artertolar resia- 
wnee. Note the inverse relation between the decrease in systemic 
versus pulmonary vewlar resistance from group A bxmnal levels 
of pulmonary artery presrere and total pulmonary resistance) to 
group C (high levels of pulmonary artery pressure and total pulmw 
nary resistance). In group C, amrinone decreased pulmonary vas- 
cular r&lance much more then it decrcesed systemic vascular 
resistance, whereas the reverse was true in weup A. See text for 
discussion. 
vated pulmonary artery pressure, amrinone reduced pulmo- 
nary arteriolar resistance more than it reduced systemic 
vascular resistance in bath the normal and high pulmonary 
vascular resistance groups but the reduction was much 
greater in the high total pulmonary resistance group (Fig. 2). 
In this group of patients, amrinone may have a striking 
beneficial effect that has obvious important clinical signifi- 
cance. 
Previous investigations. Data are scant regarding the ef- 
fects of amrinone on the pulmonary circulation. Amrinone 
may relax vascular smooth muscle by altering calcium 
transport and intracellular calcium release by a mechanism 
that is unclear at the present time. It has been shown to relax 
vascular smooth muscle (13). bovine intrapulmonw arteries 
and to decrease pulmonary arteriolar resistance in newborn 
lambs with pulmonary hypertension (14). In patients with 
pulmonary hypertension awaiting hear1 transplantation. 
Decb ct al. (15.16) showed that intravenous amrinone ther- 
apy decreased both pulmonary artery pressure and resis- 
tance. In the present study, r&none selectively vasodilated 
the pulmonary circulation in patients depending on the 
degree of pulmonary artery pressure end resistance. 
New therapeulic implicstions. Patients with pulmonar) 
artery hypertension and elevated pulmonary vascular resis- 
tance pose- difficult management problems. These patients 
are often considered inoperable uwess their increased pul- 
monary vascular resistance is reversible. Oxygen therapy is 
currently administered in the catheterization laboratory to 
determine revers;bility of elevated pulmonary vascular rcsis- 
tance (ITI. Patients with a total pulmonary resistance x3 Wood 
Um’ are considered inoperable (IS). However. in this study. 
amrimme decreased the-total pulmonary ascular resistance 
into an Operable range in three patients. Amrinone may be an 
ideal agent to add to a catheterization !aboratory protocol in 
evaluating patients with elevated pulmonary vascular rests- 
&mce due to one or more cardiac left to right shunts. 
Of paramount importance, amrinons may have an impor- 
tant therapeuric role in the management of patien,~ with a 
reactive pulmonary circulation. Althwzgh antinone is cur- 
rently used in the postoperative perirrj, its effects are 
believed 10 be attributed to ifs inotropic and systemic 
vasodilator aaion. Bemer et al. (191 qwted the admtns- 
l&ion of amrinone IO eight children afkr card~nc surgery for 
both left to righr shunto and mirrai valve replacement and 
concluded lhar amrinane acted primarily ar a systemic 
vasedilator In contrast. in our study, amrinone appeared to 
have selective vasodilator effects depending on the degree of 
pulmonary artery pressure and resistance. Although amri- 
none may be useful in patients with a normal pulmonary 
artery pressure and normal pulmonary vascular resistance, 
these patienu rarely pose significant management problems. 
Furthermore, amrinone may not be useful and even contra- 
indicated in patients with a high pulmonary artcry pressure 
and high pulmonarv Row left to ti&t shunt phvsiolow who 
are symptomatic because of puimonary bv&cir&tion. 
However. our data suggest that amtinone may have a new. 
beneficial role in patients with high pulmonary vascular 
resistance and low pulmonary Row physiology. These pa- 
tients hirtoncatly pose the most difficult management prob- 
lems and account for significant morbidity and mortality 
from reactive pulmonary hypertension in the postoperative 
wriod(ZO). lnthisgroup,amrinone may rffectiudydeere~re 
&nonq wad& &istance without causing serious syc- 
temic hypotension. These findings have important therapeu- 
tic implicationr in the man;lgement of such problematic 
patients that an commonly encountered in the practice of 
pediatric cardiology and cardiovascular surgery. 
Further prospective trials evaluating the oral bipyridinc 
derivative mikinone. which has been shown to have hemu- 
dynamic effects similar to those of amrinone with fewer side 
etTects. seem warranted to assess whether this agent will he 
beneficial in long-term management of the patient with 
elevated pulmonary vascular resistance (?I). 
